https://www.selleckchem.com/
In total, 35% of patients had CNS AEs with lorlatinib, most of grade 1 severity. Occurrence of CNS AEs did not result in a clinically meaningful difference in patient-reported quality of life. At analysis, 56% of CNS AEs had resolved (33% without intervention; 17% with lorlatinib dose modification), and 38% were unresolved; most required no intervention. Lorlatinib dose modification did not notably influence PFS. First-line lorlatinib improved PFS outcomes and reduced CNS progression versus crizotinib in patients with advanced -positive non-small-cell lung
Curtir
Comentario
Compartilhar
